Toll-like receptor 4 and Receptor for advanced glycation end-products (TLR4/RAGE)

Toll-like receptor 4 (TLR4) and the Receptor for Advanced Glycation End-products (RAGE) are two distinct pattern recognition receptors that play synergistic roles in the propagation of inflammatory responses (Source: PubMed, PMID: 24011560). TLR4 is primarily recognized for its ability to detect lipopolysaccharide (LPS) from Gram-negative bacteria, while RAGE binds a variety of ligands including advanced glycation end-products (AGEs), S100 proteins, and amyloid-beta (Source: UniProt P33765, Q15109). Both receptors share common endogenous ligands, most notably High Mobility Group Box 1 (HMGB1), and converge on downstream signaling pathways such as NF-kappaB to drive the expression of pro-inflammatory cytokines (Source: NIH, PMC3545703). This TLR4/RAGE signaling axis is critically involved in the pathogenesis of chronic inflammatory conditions, including sepsis, diabetic complications, cardiovascular disease, and neurodegeneration (Source: PubMed, PMID: 28244051). Therapeutic interventions targeting these receptors, such as the RAGE antagonist Azeliragon or TLR4 inhibitors like Resatorvid, aim to modulate hyper-inflammation, though they face challenges related to maintaining adequate host defense and managing the complexity of multi-ligand interactions (Source: ClinicalTrials.gov).

Other names

TLR4CD284AGERRAGEAdvanced glycosylation end product-specific receptor

Antagonism of receptor binding sites to prevent activation by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), thereby inhibiting downstream NF-kappaB signaling and the subsequent release of pro-inflammatory mediators (Source: PubMed, PMID: 24011560; NIH, PMC3545703).